Clinical Scorecard: Can Immunopeptidomics Redefine Cancer Immunotherapy Development?

At a Glance

Key Highlights

• Immunopeptidomics profiles antigenic peptides presented by tumor and antigen-presenting cells using LC-MS/MS.
• In PDAC research, immunopeptidomics can help identify novel T-cell targets and tumor-specific antigens, including spliced, post-translationally modified, and cryptic peptides.
• The article describes IDA/DDA as providing high-confidence fragmentation spectra for selected precursors and DIA as offering broader coverage and improved reproducibility across replicates.
• The article describes tunable EAD as a method for resolving peptide isomers, including leucine/isoleucine and aspartate/isoaspartate, while preserving labile modifications.
• Immunopeptidomics findings may inform CAR-T target selection and peptide-based vaccine development.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

• The article describes analytical challenges in detecting and characterizing diverse HLA-bound peptides, including modified peptides and sequence isomers.
• PDAC’s immunosuppressive tumor microenvironment poses challenges for CAR-T therapies.

Patient & Prescribing Data

No patient-level prescribing or treatment data are provided; the article focuses on research and analytical methods.

Immunopeptidomics findings may inform the design of CAR-T therapies and personalized peptide-based vaccines; no dosing or prescribing guidance is provided.

Clinical Best Practices

• The article describes workflows combining immunoaffinity purification, high-resolution LC-MS/MS, and bioinformatics to characterize HLA-bound peptides.
• The article describes IDA/DDA for high-confidence spectra of selected precursors and DIA for broader coverage and reproducibility.
• The article describes EAD for investigating structural isomers and labile modifications, and targeted MRM for validating and quantifying selected tumor-specific antigens.

Related Resources & Content